Charles River Laboratories Reports Q1 2026 Earnings with Revenue Growth but Declining Margins
Charles River Laboratories reported first-quarter revenue of $996 million, up slightly on a reported basis and down organically. Non-GAAP earnings per share fell by 12% year-over-year due to declining operating margins driven by higher costs related to non-human primate studies and compensation expenses.
Tickers: $CRL
Topics: non-GAAP earnings per share operating margin revenue